全文获取类型
收费全文 | 1284篇 |
免费 | 77篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 9篇 |
妇产科学 | 27篇 |
基础医学 | 159篇 |
口腔科学 | 13篇 |
临床医学 | 93篇 |
内科学 | 356篇 |
皮肤病学 | 97篇 |
神经病学 | 26篇 |
特种医学 | 98篇 |
外科学 | 152篇 |
综合类 | 7篇 |
预防医学 | 39篇 |
眼科学 | 10篇 |
药学 | 74篇 |
肿瘤学 | 194篇 |
出版年
2023年 | 9篇 |
2022年 | 17篇 |
2021年 | 25篇 |
2020年 | 11篇 |
2019年 | 16篇 |
2018年 | 38篇 |
2017年 | 35篇 |
2016年 | 19篇 |
2015年 | 21篇 |
2014年 | 28篇 |
2013年 | 36篇 |
2012年 | 64篇 |
2011年 | 59篇 |
2010年 | 37篇 |
2009年 | 36篇 |
2008年 | 49篇 |
2007年 | 52篇 |
2006年 | 45篇 |
2005年 | 61篇 |
2004年 | 59篇 |
2003年 | 72篇 |
2002年 | 56篇 |
2001年 | 47篇 |
2000年 | 37篇 |
1999年 | 44篇 |
1998年 | 19篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 9篇 |
1992年 | 36篇 |
1991年 | 38篇 |
1990年 | 44篇 |
1989年 | 41篇 |
1988年 | 32篇 |
1987年 | 26篇 |
1986年 | 22篇 |
1985年 | 29篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1977年 | 3篇 |
1976年 | 8篇 |
1973年 | 3篇 |
1968年 | 2篇 |
1965年 | 3篇 |
排序方式: 共有1364条查询结果,搜索用时 156 毫秒
51.
Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation 总被引:4,自引:0,他引:4
Hisashi Gondo Toshio Minematsu Mine Harada Koichi Akashi Shin Hayashi Shuichi Taniguchi Kazuo Yamasaki Tsunefumi Shibuya Yasushi Takamatsu Takanori Teshima Tetsuya Eto Koji Nagafuji Shin-ichi Mizuno Kenji Hosoda Ryoichi Mori Yoichi Minamishima Yoshiyuki Niho 《British journal of haematology》1994,86(1):130-137
A technique for the rapid detection of cytomegalovirus (CMV) antigen-positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV-associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase-labelled monoclonal antibody, HRP-C7, which binds an immediate-early antigen of human CMV.
CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV-associated diseases developed in 3/15 patients (20%). All patients with CMV-associated disease had a relatively large number of CMV antigen-positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen-positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV-associated disease did not develop in these patients during the period of monitoring. CMV antigen-positive leucocytes were detected more frequently in patients who developed acute graft-versus-host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV-associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen-positive blood leucocytes is useful for the diagnosis and monitoring of CMV-associated disease following bone marrow transplantation. 相似文献
CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV-associated diseases developed in 3/15 patients (20%). All patients with CMV-associated disease had a relatively large number of CMV antigen-positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen-positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV-associated disease did not develop in these patients during the period of monitoring. CMV antigen-positive leucocytes were detected more frequently in patients who developed acute graft-versus-host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV-associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen-positive blood leucocytes is useful for the diagnosis and monitoring of CMV-associated disease following bone marrow transplantation. 相似文献
52.
Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
下载免费PDF全文
![点击此处可从《Transplant infectious disease》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Takahiro Tateno Masahiro Onozawa Junichi Hashiguchi Takashi Ishio Sayaka Yuzawa Satomi Matsuoka Mizuha Kosugi‐Kanaya Kohei Okada Souichi Shiratori Hideki Goto Taichi Kimura Junichi Sugita Masao Nakagawa Daigo Hashimoto Kaoru Kahata Katsuya Fujimoto Tomoyuki Endo Takeshi Kondo Shinya Tanaka Satoshi Hashino Takanori Teshima 《Transplant infectious disease》2017,19(4)
We herein report a patient who had disseminated toxoplasmosis after hematopoietic stem cell transplantation showing atypical clinical presentation and neuroimaging. Parkinsonism symptoms such as muscle rigidity, bradykinesia, tremor, and postural instability were initial manifestations. Magnetic resonance imaging showed diffuse symmetrical lesions of bilateral basal ganglia lacking ringed enhancement. Post‐mortem analysis revealed multiple tachyzoites of Toxoplasma gondii in the basal ganglia, mid brain, cerebellum, and cardiac muscle. 相似文献
53.
Kazuo Muroi Koichi Miyamura Kazuteru Ohashi Makoto Murata Tetsuya Eto Naoki Kobayashi Shuichi Taniguchi Masahiro Imamura Kiyoshi Ando Shunichi Kato Takehiko Mori Takanori Teshima Masaki Mori Keiya Ozawa 《International journal of hematology》2013,98(2):206-213
We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 106 cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 %) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD. 相似文献
54.
55.
Occurrence of adverse events caused by valganciclovir as pre‐emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low‐dose administration
下载免费PDF全文
![点击此处可从《Transplant infectious disease》网站下载免费的PDF全文](/ch/ext_images/free.gif)
56.
Otsuki Naoki Morita Naruhiko Furukawa Tatsuya Teshima Masanori Shinomiya Hitomi Shinomiya Hirotaka Nibu Ken-ichi 《European archives of oto-rhino-laryngology》2019,276(6):1809-1814
European Archives of Oto-Rhino-Laryngology - Papillary thyroid carcinoma frequently metastasizes to central and lateral neck lymph nodes, but metastasis to retropharyngeal lymph nodes (RPLN) is... 相似文献
57.
58.
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Mamitaro Ohtsuki Akimichi Morita Atsuyuki Igarashi Shinichi Imafuku Yayoi Tada Hiroyuki Fujita Ayako Fujishige Masako Yamaguchi Rie Teshima Yumiko Tani Hidemi Nakagawa 《The Journal of dermatology》2017,44(10):1105-1111
There are limited data on the safety and efficacy of switching to secukinumab from cyclosporine A (CyA) in patients with psoriasis. The purpose of the present study was to assess the efficacy and safety of secukinumab for 16 weeks after direct switching from CyA in patients with moderate‐to‐severe psoriasis. In this multicenter, open‐label, phase IV study, 34 patients with moderate‐to‐severe psoriasis and inadequate response to CyA received secukinumab 300 mg s.c. at baseline and weeks 1, 2, 3, 4, 8 and 12. The primary end‐point was ≥75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) at week 16. The efficacy of secukinumab treatment was evaluated up to week 16, and adverse events (AE) were monitored during the study. The primary end‐point of the PASI 75 response at week 16 was achieved by 82.4% (n = 28) of patients receiving secukinumab. Early improvements were observed with secukinumab, with PASI 50 response of 41.2% at week 2 and PASI 75 response of 44.1% at week 4. AE were observed in 70.6% (n = 24) of patients, and there were no serious AE or deaths reported in the entire study period. Secukinumab showed a favorable safety profile consistent with previous data with no new or unexpected safety signals. The results of the present study show that secukinumab is effective in patients with psoriasis enabling a smooth and safe direct switch from CyA to biological therapy. 相似文献
59.
Takuwa Yasuda Toshiyuki Fukada Keigo Nishida Manabu Nakayama Masashi Matsuda Ikuo Miura Teruki Dainichi Shinji Fukuda Kenji Kabashima Shinji Nakaoka Bum-Ho Bin Masato Kubo Hiroshi Ohno Takanori Hasegawa Osamu Ohara Haruhiko Koseki Shigeharu Wakana Hisahiro Yoshida 《The Journal of clinical investigation》2016,126(6):2064-2076
Skin homeostasis is maintained by the continuous proliferation and differentiation of epidermal cells. The skin forms a strong but flexible barrier against microorganisms as well as physical and chemical insults; however, the physiological mechanisms that maintain this barrier are not fully understood. Here, we have described a mutant mouse that spontaneously develops pruritic dermatitis as the result of an initial defect in skin homeostasis that is followed by induction of a Th2-biased immune response. These mice harbor a mutation that results in a single aa substitution in the JAK1 tyrosine kinase that results in hyperactivation, thereby leading to skin serine protease overexpression and disruption of skin barrier function. Accordingly, treatment with an ointment to maintain normal skin barrier function protected mutant mice from dermatitis onset. Pharmacological inhibition of JAK1 also delayed disease onset. Together, these findings indicate that JAK1-mediated signaling cascades in skin regulate the expression of proteases associated with the maintenance of skin barrier function and demonstrate that perturbation of these pathways can lead to the development of spontaneous pruritic dermatitis. 相似文献
60.